Mark G. Eller

930 total citations
34 papers, 749 citations indexed

About

Mark G. Eller is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Molecular Biology. According to data from OpenAlex, Mark G. Eller has authored 34 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pharmacology, 11 papers in Pediatrics, Perinatology and Child Health and 8 papers in Molecular Biology. Recurrent topics in Mark G. Eller's work include Antibiotics Pharmacokinetics and Efficacy (8 papers), Pharmacological Effects and Toxicity Studies (7 papers) and Analytical Methods in Pharmaceuticals (7 papers). Mark G. Eller is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (8 papers), Pharmacological Effects and Toxicity Studies (7 papers) and Analytical Methods in Pharmaceuticals (7 papers). Mark G. Eller collaborates with scholars based in United States, United Kingdom and Belgium. Mark G. Eller's co-authors include Scott J. Weir, Anther Keung, Ronald D. Schoenwald, Charles F. Barfknecht, C. L. Beach, Lewis R. Silverman, Guido Marcucci, Richard A. Okerholm, J. Paul Phillips and Philip M. Colangelo and has published in prestigious journals such as Blood, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Mark G. Eller

33 papers receiving 700 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark G. Eller United States 17 208 156 155 139 88 34 749
Rolf Pokorny Switzerland 16 215 1.0× 63 0.4× 89 0.6× 84 0.6× 46 0.5× 23 969
H. Krüger Germany 15 151 0.7× 63 0.4× 143 0.9× 65 0.5× 108 1.2× 24 1.1k
Marcelo M. Gutierrez United States 13 129 0.6× 102 0.7× 65 0.4× 107 0.8× 129 1.5× 29 787
Shang‐Ying P. King United States 13 221 1.1× 43 0.3× 26 0.2× 121 0.9× 36 0.4× 21 928
Ka Lai Yee United States 21 179 0.9× 429 2.8× 188 1.2× 67 0.5× 170 1.9× 51 1.3k
Jaymin Shah United States 16 87 0.4× 368 2.4× 165 1.1× 71 0.5× 200 2.3× 33 843
Lane J. Brunner United States 19 242 1.2× 43 0.3× 66 0.4× 75 0.5× 156 1.8× 52 1.1k
Bertrand Diquet France 18 264 1.3× 153 1.0× 123 0.8× 94 0.7× 57 0.6× 52 1.0k
Ruth Whittington United States 13 122 0.6× 53 0.3× 53 0.3× 76 0.5× 19 0.2× 25 692
Hui C. Kimko United States 8 43 0.2× 65 0.4× 52 0.3× 102 0.7× 54 0.6× 9 513

Countries citing papers authored by Mark G. Eller

Since Specialization
Citations

This map shows the geographic impact of Mark G. Eller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Eller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Eller more than expected).

Fields of papers citing papers by Mark G. Eller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark G. Eller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Eller. The network helps show where Mark G. Eller may publish in the future.

Co-authorship network of co-authors of Mark G. Eller

This figure shows the co-authorship network connecting the top 25 collaborators of Mark G. Eller. A scholar is included among the top collaborators of Mark G. Eller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark G. Eller. Mark G. Eller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marier, Jean‐Francois, et al.. (2016). Pharmacokinetic profile of defibrotide in patients with renal impairment. Drug Design Development and Therapy. Volume 10. 2631–2641. 11 indexed citations
2.
Ohayon, Maurice M., et al.. (2014). Increased Mortality in Narcolepsy. SLEEP. 37(3). 439–444. 53 indexed citations
3.
Foreman, Mark M., Taleen Hanania, Sharon C. Stratton, et al.. (2008). In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. Pharmacology Biochemistry and Behavior. 89(4). 523–534. 16 indexed citations
4.
Foreman, Mark M., Taleen Hanania, & Mark G. Eller. (2008). Anxiolytic effects of lamotrigine and JZP-4 in the elevated plus maze and in the four plate conflict test. European Journal of Pharmacology. 602(2-3). 316–320. 9 indexed citations
5.
Marcucci, Guido, et al.. (2005). Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes. The Journal of Clinical Pharmacology. 45(5). 597–602. 117 indexed citations
6.
ZumBrunnen, Troy L., et al.. (2001). The multiple-dose pharmacokinetics of fluvoxamine in children and adolescentS. Clinical Pharmacology & Therapeutics. 69(2). 1 indexed citations
7.
Keung, Anther, Mark G. Eller, & Scott J. Weir. (1998). Pharmacokinetics of Rifapentine in Patients with Varying Degrees of Hepatic Dysfunction. The Journal of Clinical Pharmacology. 38(6). 517–524. 14 indexed citations
8.
Keung, Anther, Mark G. Eller, & Scott J. Weir. (1998). Single-dose Pharmacokinetics of Rifapentine in Elderly Men. Pharmaceutical Research. 15(8). 1286–1291. 18 indexed citations
9.
Bhargava, Vijay O., et al.. (1998). Relative Bioavailability of Cardizem CD and Tiazac Controlled-Release Diltiazem Dosage Forms After Single and Multiple Dosing in Healthy Volunteers. American Journal of Therapeutics. 5(3). 173–180. 3 indexed citations
10.
Stoltz, M., et al.. (1997). Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16 455A). Biopharmaceutics & Drug Disposition. 18(7). 645–648. 21 indexed citations
11.
Eller, Mark G., et al.. (1996). The effect of food on the relative bioavailability of deflazacort. European Journal of Drug Metabolism and Pharmacokinetics. 21(3). 241–245. 6 indexed citations
12.
Arumugham, Thangam, et al.. (1996). THE RELATIVE BIOAVAILABILITY OF TWO MARKETED CONTROLLED RELEASE DILTIAZEM DOSAGE FORMS AT STEADY STATE IN HEALTHY VOLUNTEERS. Biopharmaceutics & Drug Disposition. 17(1). 43–54. 2 indexed citations
13.
Harris, Stuart, Donald M. Hilligoss, Philip M. Colangelo, Mark G. Eller, & Richard A. Okerholm. (1995). Azithromycin and terfenadine: Lack of drug interaction*. Clinical Pharmacology & Therapeutics. 58(3). 310–315. 53 indexed citations
14.
Gupta, Suneel, et al.. (1995). Comparison of the Pharmacokinetics of Two Nicotine Transdermal Systems: Nicoderm and Habitrol. The Journal of Clinical Pharmacology. 35(5). 493–498. 23 indexed citations
15.
Eller, Mark G., et al.. (1992). Absence of food effects on the pharmacokinetics of terfenadine. Biopharmaceutics & Drug Disposition. 13(3). 171–177. 4 indexed citations
16.
Eller, Mark G., et al.. (1992). Pharmacokinetics of Terfenadine in Healthy Elderly Subjects. The Journal of Clinical Pharmacology. 32(3). 267–271. 13 indexed citations
17.
Lewis, Eric, et al.. (1991). Pharmacokinetics and Bioavailability of a New Formulation of Teicoplanin following Intravenous and Intramuscular Administration to Humans. Journal of Pharmaceutical Sciences. 80(6). 605–607. 23 indexed citations
18.
Eller, Mark G., et al.. (1989). Absorption of minoxidil after topical application: Effect of frequency and site of application. Clinical Pharmacology & Therapeutics. 45(4). 396–402. 12 indexed citations
19.
Fleishaker, Joseph C., J. Paul Phillips, Mark G. Eller, & Randall B. Smith. (1989). Pharmacokinetics and Pharmacodynamics of Alprazolam Following Single and Multiple Oral Doses of a Sustained‐Release Formulation. The Journal of Clinical Pharmacology. 29(6). 543–549. 34 indexed citations
20.
Eller, Mark G., et al.. (1989). Absorption kinetics of topical clindamycin preparations. Biopharmaceutics & Drug Disposition. 10(5). 505–512. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rolf Pokorny Breakdown of academic impact, for papers by H. Krüger Breakdown of academic impact, for papers by Marcelo M. Gutierrez Breakdown of academic impact, for papers by Shang‐Ying P. King Breakdown of academic impact, for papers by Ka Lai Yee Breakdown of academic impact, for papers by Jaymin Shah Breakdown of academic impact, for papers by Lane J. Brunner Breakdown of academic impact, for papers by Bertrand Diquet Breakdown of academic impact, for papers by Ruth Whittington Breakdown of academic impact, for papers by Hui C. Kimko
Rankless by CCL
2026